Distinguished in Hepatitis B

Wen Y. Xie

Beijing, CN 
Distinguished in Hepatitis B
Beijing, CN 
OverviewLocationsClinical Research

Overview

Wen Xie practices in Beijing, China. Xie is rated as a Distinguished expert by MediFind in the treatment of Hepatitis B. Their top areas of expertise are Hepatitis B, Cirrhosis, Hepatitis, Non-Alcoholic Fatty Liver Disease, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 106 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 30 articles and participated in 8 clinical trials in the study of Hepatitis B.

Locations

Beijing, China
Other Locations
Suzhou, China
Fengtai, 100069, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy
Precise Prediction System for Clinical Endpoint Events of Chronic Hepatitis B Patients in the Ear of Antiviral Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 06, 2022
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study
Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study
Enrollment Status: Unknown
Publish Date: December 12, 2019
Intervention Type: Drug
Study Drug: Tenofovir Disoproxil Fumarate 
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

106 Total Publications

Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD.
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: April 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xie's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile